TimesSquare Capital Management LLC Sells 6,750 Shares of ICON Public Limited (NASDAQ:ICLR)

TimesSquare Capital Management LLC cut its position in ICON Public Limited (NASDAQ:ICLR) by 3.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 203,322 shares of the medical research company’s stock after selling 6,750 shares during the quarter. TimesSquare Capital Management LLC owned about 0.25% of ICON Public worth $57,554,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Liontrust Investment Partners LLP lifted its position in ICON Public by 108.4% during the third quarter. Liontrust Investment Partners LLP now owns 89,860 shares of the medical research company’s stock worth $22,129,000 after purchasing an additional 46,739 shares during the period. Chartwell Investment Partners LLC lifted its stake in ICON Public by 16.1% during the third quarter. Chartwell Investment Partners LLC now owns 6,953 shares of the medical research company’s stock worth $1,712,000 after purchasing an additional 963 shares during the last quarter. Whittier Trust Co. increased its stake in shares of ICON Public by 6.2% in the 4th quarter. Whittier Trust Co. now owns 2,702 shares of the medical research company’s stock valued at $765,000 after purchasing an additional 158 shares during the last quarter. Cullen Investment Group LTD. acquired a new position in shares of ICON Public during the 4th quarter worth $1,620,000. Finally, Prime Capital Investment Advisors LLC acquired a new stake in ICON Public in the fourth quarter valued at about $416,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Trading Up 1.1 %

Shares of ICLR stock traded up $3.29 during trading hours on Thursday, hitting $315.04. 396,034 shares of the company were exchanged, compared to its average volume of 561,465. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.21. ICON Public Limited has a fifty-two week low of $188.45 and a fifty-two week high of $344.77. The company has a 50 day simple moving average of $319.01 and a two-hundred day simple moving average of $286.95. The firm has a market cap of $25.99 billion, a P/E ratio of 37.93, a P/E/G ratio of 1.39 and a beta of 1.18.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.13. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.08 billion. Equities analysts anticipate that ICON Public Limited will post 14.41 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Mizuho reaffirmed a “buy” rating and set a $346.00 price target on shares of ICON Public in a report on Thursday, April 4th. Truist Financial raised their price objective on ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Evercore ISI lowered their target price on ICON Public from $350.00 to $330.00 and set an “outperform” rating for the company in a report on Friday, April 26th. TD Cowen boosted their price target on ICON Public from $343.00 to $349.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Barclays raised their price objective on shares of ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, ICON Public has an average rating of “Moderate Buy” and a consensus target price of $339.44.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.